Prophylactic Antibiotic Treatment in Hemodialysis

• Status: Not yet recruiting
• Trial end date: 2028-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and severe culture negative infections, in patients on newly started hemodialysis(HD), with a central venous catheter as vascular access.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zealand University Hospital
• Treatments: Amoxicillin

Criteria

Inclusion Criteria:

• End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft))

• ≥18 years

• Ability to understand the study background, risk and benefit of treatment and to give written informed consent

Exclusion Criteria:

• Unable to give informed consent

• Known intolerance to beta-lactam antibiotics and clindamycin

• Active infection treated with antibiotics

• Breastfeeding

• Pregnancy. In women of childbearing age, an approved birth control must be ensured at least 1 month before and during all the 6 months of antibiotic/placebo treatment.

Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible.